6-K - ProQR Therapeutics N.V. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

ProQR Therapeutics N.V. announced it will host a virtual Investor and Analyst Event on April 8, 2026, titled 'Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810,' to showcase its broader RNA editing pipeline, announce new programs with clinical data readouts, and unveil the primary indication for AX-0810 ahead of anticipated target engagement data in H1 2026.

Key Takeaways

1Event date and time: April 8, 2026, 10:00 am ET to approximately 11:30 am ET

2Virtual format: Webcast presentations and Q&A with analysts and management

3Registration: https://lifescievents.com/event/g09gufqylu/

4Will announce new programs with clinical data readouts and primary indication for AX-0810

5Precedes AX-0810 target engagement data expected in H1 2026

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Exhibits (2)

6-K

FORM 6-K

99.1

EXHIBIT 99.1